Has Timothy Feyma, MD received payments from drug or device companies?

Yes. Drug and device makers reported $109,431 in general payments to Timothy Feyma, MD across 92 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Timothy Feyma, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Timothy Feyma, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Timothy Feyma, MD

Neurology with Special Qualifications in Child Neurology · Bloomington, MNNPI 1467561464

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (41.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by PTC Therapeutics, Inc. at 47.9% of the total. Among neurology with special qualifications in child neurology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$109,431in general payments, 2019–2025

Across 92 payments — averaging $1189.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

PTC Therapeutics, Inc.$52K
Acadia Pharmaceuticals Inc$50K
UCB, Inc.$5K
Ionis Pharmaceuticals, Inc.$1K
Neuropace, Inc.$1K
Jazz Pharmaceuticals Inc.$58
plus $17 from 1 others

$491,176in research payments, 2019–2025

Across 128 payments — averaging $3837.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Acadia Pharmaceuticals Inc$208K
Ionis Pharmaceuticals, Inc.$102K
Mallinckrodt Hospital Products Inc.$84K
Mallinckrodt Enterprises LLC$61K
GW Research Limited$22K
PTC Therapeutics, Inc.$12K
plus $2K from 1 others

What the payments were for

Consulting fees$34,18931%
Speaking & faculty fees$45,80042%
Travel & lodging$28,00126%
Food & beverage$1,4241%
Education$170%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
PTC Therapeutics, Inc.	44	$52,441
Acadia Pharmaceuticals Inc	25	$49,535
UCB, Inc.	9	$4,963
Ionis Pharmaceuticals, Inc.	7	$1,246
Neuropace, Inc.	4	$1,172
Jazz Pharmaceuticals Inc.	2	$58
Catalyst Pharmaceuticals, Inc.	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$109,431 in reported general payments places this provider in the 95th percentile of 34 neurology with special qualifications in child neurology providers in Minnesota.

See all neurology with special qualifications in child neurology providers in Minnesota →

Medicare billing

Part B allowed, 2024

$4,570

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
RytaryCarbidopa/Levodopa	11	$8,167
Levetiracetam	61	$2,994
LevocarnitineLevocarnitine (With Sugar)	13	$534
Valproic AcidValproic Acid (As Sodium Salt)	15	$229
Trazodone Hcl	13	$105
Trihexyphenidyl Hcl	12	$71
Temazepam	12	$47
Clonazepam	12	$25

Paid to pharmacies, not to this prescriber.

Other neurology with special qualifications in child neurology in Bloomington

Katherine FergusonBloomington$4K
Conor RyanBloomington$150
Randal RichardsonSaint Paul$89K
Nitin AgarwalSaint Paul$64K
Douglas SmithRoseville$46K
Heidi CurrierRoseville$31K
Jason DoescherSaint Paul$17K
Dimitrios ArkiloSaint Paul$8K
Laura SpeltzMinneapolis$8K
Jamie EskuriSaint Paul$6K

See the full list for Minnesota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →